Kiplinger Kiplinger
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

From $107.88 $24.99

Subscribe to Kiplinger

  • Retirement Retirement
      • Retirement
        • View all Retirement
        • Annuities
        • Estate Planning
        • Retirement Plans
        • Social Security
        • Medicare
  • Investing Investing
      • Investing
        • View all Investing
        • Stocks
        • ETFs
        • Mutual Funds
        • Bonds
        • Wealth Management
        • AI
  • Taxes Taxes
      • Taxes
        • View all Taxes
        • Tax Returns
        • Tax Deductions
        • Capital Gains Taxes
        • State Taxes
        • Tax Planning
  • Personal Finance Personal Finance
      • Personal Finance
        • View all Personal Finance
        • Savings
        • Shopping and Deals
        • Credit Cards
        • Insurance
        • Money-saving
        • Banking
  • Life Life
      • Life
        • View all Life
        • Places to Live
        • Real Estate
        • Travel
        • Careers
        • Politics
        • Business
  • Adviser Intel
  • More
    • Kiplinger Puzzles
    • Quizzes
    • Tools and Calculators
    • Kiplinger Economic Forecasts
  • Newsletters
    • Newsletter sign-up
    • Manage my newsletters
    • Latest issue of Kiplinger Today
    • Latest issue of Closing Bell
  • Subscriptions
    • Subscriptions Store
    • My Subscriptions
    • Subscriptions Help
    • Kiplinger Personal Finance
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger Investing for Income
    • Kiplinger Retirement Report
    • Kiplinger Retirement Planning
  • Newsletter sign up Newsletter
  • Trending
    • Four Ways a Massive Emergency Fund Can Hurt You More Than It Helps
    • Where the Ultra-Rich Are Buying Real Estate Now
    • 70 Valuable Things You Can Get for Free
    • The 90+ Rule of Retirement: Live Long and Prosper

    When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

    Gilead Sciences (GILD)

    Latest

    null

    Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot

    Markets Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.

    Markets
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success

      investing Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      How to Survive the Economic Fallout from COVID-19

      investing The bull market and economic expansion are over. Here's what to do now.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      5 Undervalued Stocks With Free Cash Flow to Burn

      stocks Look beyond the P/E. These five firms are inexpensive based on free cash flow.

      stocks
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Why I'm Hanging On to a Loser

      investing Gilead is way down from when I bought it, but it is flush with cash and has dozens of promising medications in its pipeline.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Can This Fallen Biotech Be Revived?

      investing I've been sorely tempted to sell my Gilead shares. But now that they're cheaper, maybe I should buy more.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      This Stumbling Biotech Stock Still Has a Lot of Promise

      investing Gilead Sciences' robust product pipeline should turn things around.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      3 Bargain Stocks to Beat the Market

      stocks The Value Line Investment Survey sees a strong year ahead for these picks.

      stocks
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Promising Bargains in Biotech Stocks

      investing What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.

      investing
    1 2
    Kiplinger Logo
    • About Us
    • Contact Future's experts
    • Terms and Conditions
    • Privacy Policy
    • Cookie Policy
    • Advertise with us

    Kiplinger is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.

    © Future US, Inc. Full 7th Floor, 130 West 42nd Street, New York, NY 10036.